Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4367187 | 1.00 | ADORA2A (0.66) | ADORA2AADORA3 | |
| SCHEMBL4367180 | 1.00 | ADORA2A (0.66) | ADORA2AADORA3 | |
| SCHEMBL4488823 | 0.90 | ADORA2A (0.65) | ADORA2AADORA3 | |
| SCHEMBL4501330 | 0.90 | ADORA2A (0.65) | ADORA2AADORA3 | |
| SCHEMBL4488839 | 0.90 | ADORA2A (0.65) | ADORA2AADORA3 | |
| Trifluoroacetic Acid SCHEMBL242979 | 0.89 | ADORA2A (0.59) | ADORA2AADORA3 | |
| SCHEMBL1402125 | 0.89 | ADORA2A (0.58) | ADORA2AADORA3 | |
| SCHEMBL13879044 | 0.89 | ADORA2A (0.58) | ADORA2AADORA3 | |
| Trifluoroacetic Acid SCHEMBL243668 | 0.87 | ADORA2A (0.60) | ADORA2AADORA3 | |
| SCHEMBL1402052 | 0.87 | ADORA2A (0.67) | ADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805181-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A-2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-08-29 | — | — | EP | disclosed |
| US-20090281127-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-11-12 | — | — | US | disclosed |
| US-20090105476-A1 | Organic Compounds | NOVARTIS AG | 2009-04-23 | — | — | US | disclosed |
| US-20080200483-A1 | Purine Derivatives for Use as Adenosin A-2A Receptor Agonists | NOVARTIS AG (CH) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281127-A1 | Organic Compounds | CYP3A43, CYP3A4, CYP2C19 | ADORA2A 2387/4885ADORA3 732/4885 |
| US-20080200483-A1 | Purine Derivatives for Use as Adenosin A-2A Receptor Agonists | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA3 3/4885 |
| US-20090105476-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | ADORA2A 2741/4885ADORA3 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.